Protein & Cell (Nov 2017)
Redirecting T cells to glypican-3 with 28.41BB.ζ and 28.ζ-41BBL CARs for hepatocellular carcinoma treatment
- Haili Ma,
- Siye Chen,
- Yan He,
- Jingwei Huang,
- Yanhong Xu,
- Chao Wang,
- Cheng Lei,
- Ting Lu,
- Shengdong Xiao,
- Jinming Mao,
- Yiyun Xu,
- Hao Guo,
- Bohua Li,
- Minghui Zhang,
- Xiaowen He
Affiliations
- Haili Ma
- Department of Discovery, Origincell Co
- Siye Chen
- Department of Discovery, Origincell Co
- Yan He
- Department of Discovery, Origincell Co
- Jingwei Huang
- Department of Discovery, Origincell Co
- Yanhong Xu
- Department of Discovery, Origincell Co
- Chao Wang
- Institute of Immunology, School of Medicine, Tsinghua University
- Cheng Lei
- Department of Discovery, Origincell Co
- Ting Lu
- Department of Discovery, Origincell Co
- Shengdong Xiao
- Department of Discovery, Origincell Co
- Jinming Mao
- Department of Discovery, Origincell Co
- Yiyun Xu
- Department of Discovery, Origincell Co
- Hao Guo
- Department of Discovery, Origincell Co
- Bohua Li
- Department of Discovery, Origincell Co
- Minghui Zhang
- Institute of Immunology, School of Medicine, Tsinghua University
- Xiaowen He
- Department of Discovery, Origincell Co
- DOI
- https://doi.org/10.1007/s13238-017-0489-0
- Journal volume & issue
-
Vol. 9,
no. 7
pp. 664 – 669
Abstract
No abstracts available.
